Skip to search form
Skip to main content
Skip to account menu
Semantic Scholar
Semantic Scholar's Logo
Search 225,302,048 papers from all fields of science
Search
Sign In
Create Free Account
razaxaban
Known as:
1-(3'-aminobenzisoxazol-5'-yl)-3-trifluoromethyl-N-(2-fluoro-4-((2'-dimethylaminomethyl)imidazol-1-yl)phenyl)-1H-pyrazole-5-carboxamide
An orally active, 1,2-benzisoxazole-containing, inhibitor of coagulation factor Xa (activated factor X) with anticoagulant activity. Razaxaban forms…
Expand
National Institutes of Health
Create Alert
Alert
Related topics
Related topics
5 relations
Narrower (2)
BMS 561389
DPC 906
Broader (2)
Isoxazoles
Pyrazoles
razaxaban hydrochloride
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
2012
2012
Warfarin and Newer Oral Anticoagulants : Long-term Prevention and Treatment of Arterial and VTE Evidence-based Synthesis Program EXECUTIVE SUMMARY BACKGROUND Thromboembolic diseases
A. A. S. Strategies
2012
Corpus ID: 37193031
Step Category Terms Result 1 Newer anticoagulants dabigatran OR desirudin OR ximelagatran OR edoxaban OR rivaroxaban OR apixaban…
Expand
2011
2011
The impact of factor Xa inhibition on axial dependent arterial thrombus formation triggered by a tissue factor rich surface
N. Pugh
,
G. Jarvis
,
Annelize Koch
,
K. Sakariassen
,
Bill Davis
,
R. Farndale
Journal of Thrombosis and Thrombolysis
2011
Corpus ID: 33690234
This study was designed to assess the effect of Factor Xa antagonists on thrombus formation at various axial positions on a…
Expand
Review
2009
Review
2009
[Advances in antithrombotic treatment--antithrombotics with anti-Xa effect].
A. Bátorová
Vnitrni lekarstvi
2009
Corpus ID: 5691072
The use of anticoagulants in the prophylaxis and treatment of arterial and venous thrombosis has substantially expanded during…
Expand
2006
2006
New anticoagulants and the management of their bleeding complications
H. Ng
,
M. Crowther
2006
Corpus ID: 73267923
SUMMARY Limitations of the currently available anticoagulants have fanned the continuing search for new anticoagulants with…
Expand
Review
2005
Review
2005
Heterogeneity of synthetic factor Xa inhibitors.
G. Gerotziafas
,
M. Samama
Current pharmaceutical design
2005
Corpus ID: 22508447
Heparins and vitamin K antagonists are the landmarks of antithrombotic treatment. Both of them were discovered by serendipity…
Expand
Review
2004
Review
2004
New anticoagulants and their potential impact on the treatment of thromboembolic disease.
J. Ansell
Current hematology reports
2004
Corpus ID: 8593891
Traditional anticoagulants have drawbacks that make them complex to manage, limit their usefulness, and increase the possibility…
Expand
Review
2003
Review
2003
Preparing for the New Anticoagulants
B. Davidson
Journal of Thrombosis and Thrombolysis
2003
Corpus ID: 26416991
New anticoagulant agents with differing properties, risks, and potential economic consequences are becoming available. Two…
Expand
By clicking accept or continuing to use the site, you agree to the terms outlined in our
Privacy Policy
(opens in a new tab)
,
Terms of Service
(opens in a new tab)
, and
Dataset License
(opens in a new tab)
ACCEPT & CONTINUE